New malaria lead kills 99.9% of pathogens
Dutch and US researchers have re-engineered non-druggable compounds that block the transmission and metabolism of the malaria parasite Plasmodium falciparum.
Versantis raises CHF16m in Series B financing
Swiss Versantis AG has raised money in order to advance its liver detoxifying candidate VS-01 from ongoing Phase Ia trials to initial Phase IIa efficacy proof.
Lundback swallows migraine drug maker Alder
Danish Lundbeck AS is has secured a stake in the migraine market by paying US$1.95bn (1.76bn) to acquire Alder BioPharmaceuticals Inc.
PFF Group NV acquires stake in Autolus Therapeutics
Prague-based PPF Group has acquired a 19.2% stake in Autolus Therapeutics plc, a developer of T cell cancer therapies.
Researchers identify CTLA-4 response marker
German and US researchers have found a biomarker that identifies tumours responding to CTLA-4 checkpoint blockers.
Inotrem SA raises 39m to provide POC for nangibotide
French biotech Inotrem SA raised 39m to finance Phase IIb efficacy testing of its TREM1 blocker nangibotide (Motrem) in patients with septic shock.
Ermium Therapeutics bags 6.3m in Series A round
Paris-based Ermium Therapeutics has completed a Series A financing to develop breakthrough auto-immune therapeutics.
Pharvaris BV raises $66m to advance oral HAE drug
Leiden-based Pharvaris BV received a cash injection that will be used to push PHA121, the very first orally administered hereditary angioedema (HAE) drug.
4BIO Ventures launches US$50m fund
London and Boston-based 4BIO Ventures has raised US$50m to target early-stage developers of advanced therapies by means of its new 4Bio Ventures II fund.